At Sprout Pharmaceuticals, we’re endeavoring to breakthrough with the first FDA approved treatment for women’s most common sexual dysfunction. Based in Raleigh, NC, the company is focused solely on the delivery of a treatment option for the unmet need of women with Hypoactive Sexual Desire Disorder (HSDD), or distressing low sexual desire. Sprout is pursuing the FDA approval of flibanserin to treat HSDD in premenopausal women, for which there is currently no FDA-approved treatment.
Sit At Our Glass Table
Novel ideas fuel our entrepreneurial passion. Sit with us at our glass table, where we have lunch together daily, to get a taste of our culture. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what we’re trying to collectively accomplish.
We’re On A Mission
Singular in our focus, our leadership team sold off a successful business in male sexual health to take on the pursuit of this much needed scientific and societal breakthrough for women. Led by a woman dedicated to this first for women, our CEO, Cindy Whitehead, and the work of the committed Sprout team has been featured on news outlets including ABC 20/20, Yahoo! News with Katie Couric, Good Morning America, Nightline, Huffington Post, and CBS This Morning.
Learn Our Latest
Sprout Pharmaceuticals Appeals FDA Decision on New Drug Application for Flibanserin to Treat Hypoactive Sexual Desire Disorder in Premenopausal Women
FDA Accepts Appeal Filed through Formal Dispute Resolution Process — December 11, 2013